STAT

Joe Biden may resurface a long-held dream: a White House laser-focused on cancer

Joe Biden has spent the last two years outside politics, advocating for better cancer cures and patient access. How will his legacy as the country’s de facto cancer czar play…
Former Vice President Joe Biden in the Rose Garden in 2015, as he announced he would not run for president in 2016.

WASHINGTON — Barely five months after his son’s death from brain cancer, a bereaved Vice President Joe Biden announced to the nation he would not run for president in 2016 — and immediately pinpointed his deepest regret.

“If I could be anything, I would have wanted to be the president that ended cancer,” he said in a Rose Garden address in October 2015. “Because it’s possible.”

Biden’s announcement that he will run for president in 2020, however, has resurfaced his dream: a White House that makes cancer a signature issue, backed by a politician whose life was so publicly upended by the disease. With much of the early debate in the Democratic primary centering on health care, Biden’s stint as cancer-advocate-in-chief and orchestrator of the Obama administration’s “cancer moonshot” could give him the opportunity to make the disease, its treatments, and his own grief central to the presidential election.

After leaving office, Biden structured his cancer-fighting efforts in a way that could suit a possible campaign. The Biden Cancer Initiative — the pillar of Biden’s policy work since leaving office — raised $10 million in the year following its incorporation. The nonprofit did not accept contributions from pharmaceutical companies, in an effort both to preserve independence and avoid the political pitfalls associated with an increasingly vilified drug industry.

The Bidens have fostered

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks